Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Lilly Backs Broad Diabetes Range to Challenge Rivals
Lilly Backs Broad Diabetes Range to Challenge Rivals
Lilly Backs Broad Diabetes Range to Challenge Rivals
Submitted by
admin
on October 8, 2012 - 12:53pm
Source:
Bloomberg
News Tags:
Eli Lilly
diabetes
Boehringer Ingelheim
Amylin
LY2605541
GLP-1 agonist
SGLT2 inhibitor
Headline:
Lilly Backs Broad Diabetes Range to Challenge Rivals
Do Not Allow Advertisers to Use My Personal information
